Boryeong, Approval Granted for Phase 3 Plan of Improved Hypertension and Dyslipidemia Combination Drug
Boryung announced on the 15th that it has received approval from the Korean Ministry of Food and Drug Safety for the Phase 3 clinical trial plan of the improved new drug combination BR1018 for hypertension and dyslipidemia.
Hot Picks Today
At President Lee's Call to "Give Enough to Shock," Whistleblower Rewards Become a Real Lottery
- If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Lee Warns "Do Not Cross the Line" as Minister Steps In... Behind the Scenes of Defusing the Samsung Strike Crisis
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
This trial aims to compare and evaluate the efficacy and safety of combined administration of BR1018B and BR1018C in patients with essential hypertension and primary hypercholesterolemia. It will be conducted over approximately 24 months with 156 domestic patients. The clinical trial period is scheduled from this month until August next year.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
